{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:22:43Z","timestamp":1790252563084,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T00:00:00Z","timestamp":1544572800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s12012-018-9499-2","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T02:19:21Z","timestamp":1544581161000},"page":"382-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib"],"prefix":"10.1007","volume":"19","author":[{"given":"Daryl","family":"Sudasena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinu Valentin","family":"Balanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Donisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saamir","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Palaskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Karimzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lopez-Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Arain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Lance","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8817-4579","authenticated-orcid":false,"given":"Cezar","family":"Iliescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,12]]},"reference":[{"key":"9499_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","volume":"53","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir, H., Ethier, J. L., Lee, D. S., Thavendiranathan, P., & Amir, E. (2017). Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev, 53, 120\u2013127.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"9499_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","volume":"163","author":"RM Steingart","year":"2012","unstructured":"Steingart, R. M., Bakris, G. L., Chen, H. X., Chen, M. H., Force, T., Ivy, S. P., et al. (2012). Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J, 163(2), 156\u2013163.","journal-title":"Am Heart J"},{"issue":"1","key":"9499_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","volume":"1","author":"PS Hall","year":"2013","unstructured":"Hall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013). The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail, 1(1), 72\u201378.","journal-title":"JACC Heart Fail"},{"issue":"17","key":"9499_CR4","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMc1108849","volume":"365","author":"I Uraizee","year":"2011","unstructured":"Uraizee, I., Cheng, S., & Moslehi, J. (2011). Reversible cardiomyopathy associated with sunitinib and sorafenib. N Engl J Med, 365(17), 1649\u20131650.","journal-title":"N Engl J Med"},{"issue":"36","key":"9499_CR5","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano, J. L., Lancellotti, P., Rodriguez Munoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., et al. (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J, 37(36), 2768\u20132801.","journal-title":"Eur Heart J"},{"issue":"11","key":"9499_CR6","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1161\/CIRCRESAHA.114.303200","volume":"114","author":"JM Duran","year":"2014","unstructured":"Duran, J. M., Makarewich, C. A., Trappanese, D., Gross, P., Husain, S., Dunn, J., et al. (2014). Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res, 114(11), 1700\u20131712.","journal-title":"Circ Res"},{"issue":"32","key":"9499_CR7","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","volume":"26","author":"M Schmidinger","year":"2008","unstructured":"Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., et al. (2008). Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 26(32), 5204\u20135212.","journal-title":"J Clin Oncol"},{"issue":"11","key":"9499_CR8","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/annonc\/mdm489","volume":"18","author":"M Mego","year":"2007","unstructured":"Mego, M., Reckova, M., Obertova, J., Sycova-Mila, Z., Brozmanova, K., & Mardiak, J. (2007). Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol, 18(11), 1906\u20131907.","journal-title":"Ann Oncol"},{"issue":"7","key":"9499_CR9","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/02841860903229124","volume":"48","author":"GS Orphanos","year":"2009","unstructured":"Orphanos, G. S., Ioannidis, G. N., & Ardavanis, A. G. (2009). Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol, 48(7), 964\u2013970.","journal-title":"Acta Oncol"},{"issue":"15","key":"9499_CR10","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/cncr.30680","volume":"123","author":"G Battipaglia","year":"2017","unstructured":"Battipaglia, G., Ruggeri, A., Massoud, R., El Cheikh, J., Jestin, M., Antar, A., et al. (2017). Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Cancer, 123(15), 2867\u20132874.","journal-title":"Cancer"},{"issue":"4","key":"9499_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/his.12277","volume":"64","author":"T Tsuzuki","year":"2014","unstructured":"Tsuzuki, T., Sassa, N., Shimoyama, Y., Morikawa, T., Shiroki, R., Kuroda, M., et al. (2014). Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism. Histopathology, 64(4), 484\u2013493.","journal-title":"Histopathology"},{"issue":"6","key":"9499_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","volume":"12","author":"RM Touyz","year":"2018","unstructured":"Touyz, R. M., Herrmann, S. M. S., & Herrmann, J. (2018). Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens, 12(6), 409\u2013425.","journal-title":"J Am Soc Hypertens"},{"issue":"2","key":"9499_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jamadermatol.2015.3209","volume":"152","author":"VJ Shi","year":"2016","unstructured":"Shi, V. J., Galan, A., Odell, I. D., & Choi, J. N. (2016). Cutaneous vasculopathy as an adverse effect of the anti-vascular endothelial growth factor agent axitinib. JAMA Dermatol, 152(2), 222\u2013223.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"9499_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/2047487318755193","volume":"25","author":"M Totzeck","year":"2018","unstructured":"Totzeck, M., Mincu, R. I., Mrotzek, S., Schadendorf, D., & Rassaf, T. (2018). Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol, 25(5), 482\u2013494.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"9499_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jjcc.2009.03.009","volume":"54","author":"Y Arima","year":"2009","unstructured":"Arima, Y., Oshima, S., Noda, K., Fukushima, H., Taniguchi, I., Nakamura, S., et al. (2009). Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol, 54(3), 512\u2013515.","journal-title":"J Cardiol"},{"issue":"2","key":"9499_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","volume":"9","author":"S Wu","year":"2008","unstructured":"Wu, S., Chen, J. J., Kudelka, A., Lu, J., & Zhu, X. (2008). Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol, 9(2), 117\u2013123.","journal-title":"Lancet Oncol"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-018-9499-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-018-9499-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-018-9499-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T19:21:36Z","timestamp":1576092096000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-018-9499-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,12]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["9499"],"URL":"https:\/\/doi.org\/10.1007\/s12012-018-9499-2","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,12]]},"assertion":[{"value":"12 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from the patient presented in this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}